Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2R | P25116 | 6/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL1732487 | 0.86 | F2R (0.35) | F2R | |
| Bromide SCHEMBL1732511 | 0.85 | F2R (0.39) | F2R | |
| Bromide SCHEMBL5494493 | 0.83 | F2R (0.34) | F2R | |
| Bromide SCHEMBL1729506 | 0.82 | F2R (0.38) | F2R | |
| Bromide SCHEMBL1729648 | 0.81 | F2R (0.40) | F2R | |
| Hydrochloric Acid SCHEMBL1732787 | 0.80 | F2R (0.39) | F2R | |
| Bromide SCHEMBL1732842 | 0.79 | F2R (0.35) | F2R | |
| Bromide SCHEMBL5483188 | 0.78 | F2R (0.35) | F2R | |
| Bromide SCHEMBL1732601 | 0.78 | F2R (0.36) | F2R | |
| SCHEMBL14449091 | 0.78 | F2R (0.41) | F2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1973407-B1 | SPIRO COMPOUNDS AND METHODS OF USE | CHEN GUOQING PAUL (US) | 2011-11-23 | — | — | EP | disclosed |
| US-20110237794-A1 | Spiro Compounds And Methods Of Use | CHEN GUOQING PAUL | 2011-09-29 | — | — | US | disclosed |
| US-7977346-B2 | Spiro compounds and methods of use | CHEN GUOQING PAUL | 2011-07-12 | — | — | US | disclosed |
| EP-1973407-A2 | SPIRO COMPOUNDS AND METHODS OF USE | Chen, Guoqing Paul (US) | 2008-10-01 | — | — | EP | disclosed |
| WO-2007084875-A2 | SPIRO COMPOUNDS AND METHODS OF USE | CHEN GUOQING PAUL (US) | 2007-07-26 | — | — | WO | disclosed |
| US-20070167470-A1 | Spiro compounds and methods of use | CHEN GUOQING P | 2007-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237794-A1 | Spiro Compounds And Methods Of Use | TEK, KDR, EGFR | F2R 1775/4885 |
| US-20070167470-A1 | Spiro compounds and methods of use | TEK, KDR, EGFR | F2R 1775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.